CancerApex Bioscience discovers new PDE4 and PDE5 inhibitorsApex Bioscience Inc. has presented phosphodiesterase PDE4 and cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A; PDE5) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease (COPD), heart failure, hepatic fibrosis, inflammatory bowel disease, rheumatoid arthritis, idiopathic pulmonary fibrosis and Alzheimer’s disease, among others.